Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1993 September; 68(3): 457–459.
PMCID: PMC1968384

Surrogate endpoints.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (644K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. [PubMed]
  • Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979 Oct 4;301(14):743–748. [PubMed]
  • Boice JD, Jr, Greene MH, Killen JY, Jr, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni JF., Jr Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983 Nov 3;309(18):1079–1084. [PubMed]
  • Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130. [PubMed]
  • Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 1;118(9):674–680. [PubMed]
  • Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. [PubMed]
  • Coltman CA, Jr, Dixon DO. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep. 1982 Apr;66(4):1023–1033. [PubMed]
  • Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991 Nov 23;338(8778):1281–1285. [PubMed]
  • Ellenberg S, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat Med. 1989 Apr;8(4):405–413. [PubMed]
  • Ellenberg SS. Surrogate end points in clinical trials. BMJ. 1991 Jan 12;302(6768):63–64. [PMC free article] [PubMed]
  • Gerber GS, Chodak GW. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol. 1990 Nov;144(5):1177–1179. [PubMed]
  • Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12;302(6768):73–78. [PMC free article] [PubMed]
  • Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going? Ann Intern Med. 1992 Apr 1;116(7):599–601. [PubMed]
  • Lavin PT, Flowerdew G. Studies in variation associated with the measurement of solid tumors. Cancer. 1980 Sep 1;46(5):1286–1290. [PubMed]
  • Machado SG, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr. 1990;3(11):1065–1073. [PubMed]
  • Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976 Jul;38(1):388–394. [PubMed]
  • Reimer RR, Hoover R, Fraumeni JF, Jr, Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. [PubMed]
  • Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM. Therapeutic alternatives for hormone-refractory prostatic cancer. Semin Urol. 1992 Feb;10(1):55–64. [PubMed]
  • Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992 Mar;147(3 Pt 2):931–934. [PubMed]
  • Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. [PubMed]
  • Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2(2):114–124. [PubMed]
  • Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984 Sep;2(9):1040–1046. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK